Production (Stage)
Mydecine Innovations Group Inc.
MYCO
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -42.50% | 24.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 117.83% | -221.02% | |||
| Operating Income | -117.83% | 221.02% | |||
| Income Before Tax | -111.55% | 223.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -111.55% | 223.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -111.55% | 223.49% | |||
| EBIT | -117.83% | 221.02% | |||
| EBITDA | -- | 221.36% | |||
| EPS Basic | -111.60% | 224.15% | |||
| Normalized Basic EPS | -131.53% | 175.00% | |||
| EPS Diluted | -111.60% | 224.15% | |||
| Normalized Diluted EPS | -131.53% | 175.00% | |||
| Average Basic Shares Outstanding | 0.20% | -0.20% | |||
| Average Diluted Shares Outstanding | 0.20% | -0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||